echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Haematol: Combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells or a new therapy for the treatment of relapsed or refractory multiple myeloma

    Lancet Haematol: Combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells or a new therapy for the treatment of relapsed or refractory multiple myeloma

    • Last Update: 2021-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy has been shown to be active in patients with relapsed or refractory multiple myeloma.


    The study included patients with multiple myeloma between the ages of 18 and 69, and the Kanofsky performance score was above 50, and it met the international myeloma working group's diagnostic criteria for relapsed or refractory diseases .


    diagnosis

     

    From May 1, 2017 to January 20, 2019, a total of 22 patients were enrolled in the study, and 21 patients received CAR T cell infusion, and safety and activity analysis and evaluation were available.


    In summary, the results of this study confirm that the combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells is feasible in patients with relapsed or refractory multiple myeloma.


    CAR-T

     

    Original source:

     

    Zhiling Yan, et al.


    ncbi.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.